Can viruses that eat bacteria beat lung infections? new study seeks answers
NCT ID NCT07076238
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is recruiting 100 adults with hard-to-treat nontuberculous mycobacterial (NTM) lung infections to see if phage therapy—using viruses that kill bacteria—can help. Researchers will collect blood and airway samples to find biological markers that show whether the treatment is working. The goal is not to test the therapy itself, but to learn how to tell if it's effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bacteriophage treatment (mycobacteriophage)
- What this could lead to
- If successful, this study could identify biological markers that predict whether phage therapy is working, helping doctors personalize treatment for stubborn bacterial lung infections.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (100 people) and early-stage, so results may not apply broadly. Phage therapy itself may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.